Core Viewpoint - Quantum BioPharma Ltd. has successfully completed a Phase 1 trial for its compound Lucid-MS, which showed no safety concerns and was well-tolerated in healthy participants, paving the way for future clinical development [1][3][4] Group 1: Trial Results - The final safety review committee found that Lucid-MS was well-tolerated with no serious adverse events reported during the trial [1] - The trial was a Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants [1] Group 2: Product Information - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound aimed at treating multiple sclerosis (MS) by stabilizing the myelin sheath surrounding nerve fibers [2] - The compound is a patented New Chemical Entity (NCE) that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models [5] Group 3: Future Development Plans - The completion of the Phase 1 trial allows the company to move forward with plans for a Phase 2 trial in MS patients [3][4] - The company aims to achieve drug approval and commercialization of Lucid-MS, focusing on arresting demyelination in MS [4] Group 4: Company Overview - Quantum BioPharma is dedicated to developing innovative solutions for neurodegenerative and metabolic disorders, with a focus on its lead compound, Lucid-MS [5] - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of unbuzzd™, a product related to its portfolio [5]
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302